Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00501228 · ClinicalTrials.gov registry record · NA

Tissue Repair in Stem Cell Transplant Recipients

A NA study, sponsored by M.D. Anderson Cancer Center.

Terminated
Registry status
NA
Development phase
2
Enrollment target

NCT00501228: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.

NCT00501228 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00501228, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.

TERMINATED
Registry status
NA
Development phase
2 participants
Enrollment target

Study Summary

Primary Objective: 1\. To determine whether rhG-CSF treatment will increase the frequency of donor-derived cells contributing to repair of damaged epithelial/endothelial or solid organ-specific tissue caused by graft-versus-host disease (GVHD) in patients who underwent sex-mismatched stem cell transplantation. Secondary Objective: 1\. To determine whether rhG-CSF treatment can alleviate GVHD-induced damage to epithelial/endothelial or solid organ-specific tissue.

Primary Outcome

In each patient, the number of donor derived (dd) cells in solid organ tissue specimens measured by biopsy of relevant tissue at initiation of rhG-CSF treatment (baseline) and at eight weeks post allogeneic transplant.

Interventions

  • DRUG Filgrastim

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2003-02
Est. Completion 2008-09
Phase NA
M.D. Anderson Cancer Center

2,692 total trials

Why NCT00501228 stopped before completion

NCT00501228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 1 intervention - of which Filgrastim is the first listed.

NCT00501228 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00501228 about?

NCT00501228 is a clinical study titled "Tissue Repair in Stem Cell Transplant Recipients". Primary Objective: 1\. To determine whether rhG-CSF treatment will increase the frequency of donor-derived cells contributing to repair of damaged epithelial/endothelial or solid organ-specific tissue caused by graft-versus-host disease (GVHD) in patients who underwent sex-mismatched stem cell tran...

What is the current status of trial NCT00501228?

This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2003-02. Estimated completion is 2008-09.

What interventions are being tested in trial NCT00501228?

The interventions under investigation include: Filgrastim (DRUG).

Who is sponsoring clinical trial NCT00501228?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00501228's enrollment target sits among peer trials

2 1997th of 2000 the lowest of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00501228, the US trial registry maintained by the National Library of Medicine. NCT00501228 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.